Edition:
United States

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

4.62USD
19 Jan 2017
Change (% chg)

-- (--)
Prev Close
$4.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
539,996
52-wk High
$65.70
52-wk Low
$4.53

OPHT.OQ

Chart for OPHT.OQ

About

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascu... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $164.92
Shares Outstanding(Mil.): 35.70
Dividend: --
Yield (%): --

Financials

  OPHT.OQ Industry Sector
P/E (TTM): -- 44.51 30.50
EPS (TTM): -4.60 -- --
ROI: -45.89 -1.38 14.85
ROE: -699.82 -1.00 16.27

BRIEF-Ophthotech on Dec. 16, 2016 announced reduction in personnel is expected to involve about 80 pct of workforce

* Ophthotech -on dec 16, 2016, co announced that it had determined to implement a reduction in personnel to focus on an updated business plan

Jan 17 2017

BRIEF-Ophthotech says provided written notice to Ajinimoto Althea Inc terminating capacity reservation agreement - SEC filing

* Ophthotech - on January 5, co provided written notice to Ajinimoto Althea Inc terminating capacity reservation agreement - SEC filing

Jan 06 2017

BRIEF-Ophthotech Q3 loss per share $1.71

* Collaboration revenue was $1.7 million for quarter ended September 30, 2016, compared to $3.4 million for prior year period.

Nov 08 2016

BRIEF-Ophthotech Corp & Ajinomoto Althea entered into a clinical and commercial services agreement

* Ophthotech Corp - Co, Ajinomoto Althea, Inc. entered into a clinical and commercial services agreement - SEC filing

Nov 04 2016

BRIEF-Ophthotech Q2 loss per share $0.85

* Q2 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S

Aug 03 2016

Earnings vs. Estimates